A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether augmentation of antidepressant medication with Omega-3 polyunsaturated fatty acids increases the speed and degree of improvement for patients with major depression

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of New South Wales
• Collaborators: Ocean Nutrition; Sphere Healthcare; Your Health Inc.
• Treatments: Antidepressive Agents

Criteria

Inclusion Criteria:

• Participants must present with a first or new episode of DSM IV non-psychotic major depression warranting treatment with antidepressant mediation.

• Must be able to give informed consent.

Exclusion Criteria:

• History of psychosis or mania/hypomania or personality disorder.

• Non-English speaking or otherwise unable to provide historical information.

• Having taken Omega-3 dietary supplements in the last 3 months.

• History of allergy to Omega-3 supplements, finfish or shellfish.

• Pregnancy, breast feeding or plans to become pregnant during course of study.

• Post-natal depression

• Current drug or alcohol abuse or dependence or history of abuse or dependence over the last 12 months.

• Unstable thyroid function

• Hepatic or renal impairment or other medical conditions that may interfere with the absorption and metabolism of Omega-3 polyunsaturated fatty acids

• Coagulopathy or anticoagulant treatment due to theoretical bleeding risk.

• Patients who, in the investigator's judgment pose a current serious suicidal or other safety risk, or patients who will not likely be able to comply with the study protocol.